No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.

Date publication

août 2016

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier

Tous les auteurs :
Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27217453

Résumé

We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up.

Mots clés

Adult, Female, Fertility, drug effects, Fertility Preservation, methods, Gonadotropin-Releasing Hormone, agonists, Humans, Lymphoma, drug therapy, Middle Aged, Norethindrone, therapeutic use, Ovary, drug effects, Primary Ovarian Insufficiency, prevention & control, Prospective Studies, Triptorelin Pamoate, administration & dosage

Référence

J. Clin. Oncol.. 2016 08 1;34(22):2568-74